News
DDW: Ozanimod active in moderate-severe UC, without cardiac signal in TOUCHSTONE trial
Key clinical point: Ozanimod 1 mg induced clinical remission at week 8 in patients with moderate to severe ulcerative colitis. Major finding: At...
News
VIDEO: Stroop app predicts hepatic encephalopathy
The Stroop App is a smartphone screening tool that tests the patient’s cognitive speed and flexibility, which physicians can administer themselves...
News
The GLUTOX Trial: Getting closer to identifying nonceliac gluten sensitivity
WASHINGTON – A simple dietary challenge may help identify nonceliac gluten sensitivity in patients with gastrointestinal functional disorders,...
Video
DDW: VIDEO: What we don’t know in the management of liver disease and coagulopathy
WASHINGTON – Your patient has cirrhosis, platelets 60,000 mm3, an INR of 2.0, serum creatinine of 1.2 mg/dL, and requires an endoscopic retrograde...
News
AACR: HPV vaccine may protect some women with prior exposure
Key clinical point: HPV vaccination provided strong protection at multiple anatomic sites in women without prior HPV exposure, and may still offer...
News
ABA: Childhood burn survivors risk more physical, mental disorders
Key clinical point: Adult survivors of childhood burn injuries have increased rates of Axis I mental and physical disorders. Major finding: 81% of...
News
ABA: Rehab time linked to outcomes in all burn patients
Key clinical point: Rehabilitation time was associated with reduced risk of scar contracture and lost range of motion in burn patients. Major...
News
VA study whittles obesity paradox in RA down to size
Key clinical point: Weight loss is a strong independent predictor of death in rheumatoid arthritis. Major finding: Weight loss of more than 3 kg/...
News
AACR: IMCgp100 activity eyed in ocular melanoma
Key clinical point: IMCgp100 is clinically active in advanced melanoma, including ocular melanoma and patients refractory to immunotherapy. Major...
News
AACR: Targeted combo active in triple-negative breast cancer, ovarian cancer
Key clinical point: Combining the PARP inhibitor olaparib and the investigational P13K inhibitor BKM 120 is safe and active in triple-negative...
News
AACR: Biomarker of response to olaparib found
Key clinical point: Genomic defects, most commonly in BRCA2 and ATM, were associated with olaparib response in metastatic castration-resistant...
News
Ischemic preconditioning fails to shift CABG outcomes
Key clinical point: Remote ischemic conditioning prior to CABG did not improve outcomes at 1 year. Major finding: Cardiovascular death, MI, stroke...
News
AACR: KEYNOTE-001 takes step toward PD-L1 blocker biomarker
Key clinical point: Pembrolizumab provided durable responses in NSCLC, with clinical outcomes correlating with a proposed biomarker. Major finding...